Charles River Labs CFO Resignation and Interim Appointment

An update from Charles River Labs ( (CRL) ) is now available.

On September 12, 2025, Flavia H. Pease announced her resignation as Chief Financial Officer of Charles River Laboratories, effective September 29, 2025, to pursue another opportunity. Her departure is not due to any disagreements with the company. Michael G. Knell, the Corporate Senior Vice President and Chief Accounting Officer, has been appointed as the interim CFO. The company has begun a search for a permanent successor. Charles River Laboratories reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, indicating confidence in its market position and long-term growth opportunities.

The most recent analyst rating on (CRL) stock is a Hold with a $161.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.

Spark’s Take on CRL Stock

According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.

Charles River Labs’ overall score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio. The earnings call provides some optimism with improved guidance and strategic cost reductions, but ongoing challenges in key segments remain a concern.

To see Spark’s full report on CRL stock, click here.

More about Charles River Labs

Charles River Laboratories is a company that provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and leading academic institutions. The company focuses on supporting early-stage drug development needs.

Average Trading Volume: 876,372

Technical Sentiment Signal: Sell

Current Market Cap: $7.49B

For detailed information about CRL stock, go to TipRanks’ Stock Analysis page.